SHINE Technologies is headquartered in Janesville, Wisconsin. Phoenix, our manufacturing division, operates a manufacturing facility and industrial imaging center in Fitchburg, Wisconsin. We are expanding rapidly, with new facilities under construction in Janesville and facilities slated for construction in the Netherlands and on the West Coast of the United States.

Janesville, Wisconsin

Global headquarters

We are headquartered in Janesville, Wisconsin. Our new headquarters opened in August 2021 and is constructed adjacent to our medical isotope production facility on our 105-acre campus across from the Southern Wisconsin Regional Airport. In 2020, we broke ground on the new 35,000-square-foot facility. Previously, SHINE’s corporate headquarters had been in downtown Janesville.

Building-OneBuilding One

Building One is our state-of-the-art technology development center as well as small-scale therapeutic isotope production facility for lutetium-177 (Lu-177). We broke ground on the facility in 2017 with the initial intent to house the first fully integrated, full-size molybdenum-99 (Mo-99) production system for training employees and developing operating history with the equipment. The building continues to be used for that function today, as well as operating as a bridge production facility for Lu-177. We will continue to produce Lu-177 under cGMP conditions at Building One while the large-scale facility (Cassiopeia) is under construction.

The Chrysalis

SHINE’s Mo-99 production facility for neutron-generated isotopes, called The Chrysalis, will be the largest dedicated medical isotope production facility in the world. We broke ground on the 43,000-square-foot facility in 2019 and finished building the exterior structure in the first quarter of 2021. In this facility we will be using a patented, proprietary manufacturing process to produce medical isotopes such as Mo-99, an essential component in medical imaging procedures such as SPECT scans. At full capacity, we believe the facility will be capable of satisfying the current patient demand for Mo-99 in the United States or the equivalent of over one-third of the world’s current total demand.


SHINE Therapeutics is focused on addressing the need for therapeutic isotopes used to treat cancer, and those isotopes will be produced in Cassiopeia. Such isotopes include Lu-177, which is used in cancer treatment along with a disease-targeting molecule to destroy tumor cells while leaving healthy cells unharmed. At Cassiopeia, SHINE Therapeutics will produce Lu-177 and will branch out into producing other therapeutic isotopes, as well. We expect this to be the largest production facility for Lu-177 in the world with a capacity of 200,000 patient doses per year.

Fitchburg, Wisconsin


Heliopolis, a 50,000-square-foot facility, is home to SHINE’s Systems and Manufacturing division, which provides production and R&D space for developing and building neutron generators. This equipment is used in our medical isotope production and industrial materials testing systems, as well as for clients in the aerospace, defense, and energy sectors.

Imaging center

Located adjacent to Heliopolis, our imaging center is a first-of-its-kind commercial neutron-based imaging facility. The 10,000-square-foot facility provides a full suite of industrial radiography services including neutron radiography, X-ray imaging, and X-ray and neutron computed tomography, all without the need for a nuclear reactor.


Veendam, the Netherlands

Medical isotope production facility

Veendam, the Netherlands, has been selected as the site of our first European medical isotope production facility. The new facility will leverage the Janesville facility’s layout to support a similar Mo-99 production capacity in our European facility and allow us to deliver a reliable, flexible supply of critical medical isotopes, including Mo-99 and other diagnostic and therapeutic isotopes, to European customers. This facility will have a similar layout and production capacity to the Mo-99 production in Janesville. Funding to begin designing the facility was secured in early 2022. Our European team is currently working through the design and licensing process. Construction of the Veendam facility is expected to begin in 2023, with commercial production anticipated to start in 2026. We expect this facility to have similar capacity to our U.S. facility with production capacity greater than the current European demand for Mo-99.